Sanjay Maraboyina, MD

Research Program: Cancer Therapeutics Faculty Rank: Assistant Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Radiation Oncology

Cancer Research Interest

• Disease Site Focus: GU, Musculoskeletal, Thoracic/ Lung
• Research Focus Area: Health Disparities, Treatment, Diagnosis/ Prognosis
• Type of Research: Clinical

Contact Information

• Email Address: SMARABOYINA@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “NRG-GU012 - Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)” (NCT05327686)
• “NRG GU010 “Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)”” (NCT05050084)
• “NRG-GU008 Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE*)* INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy” (NCT04134260)
• “NRG GU009 - Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*) ” (NCT04513717)
• “S1914 - A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC” (NCT04214262)

Active Grants

• NRG Oncology Foundation – NRG-GU009
  “Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*) (273360)”
  Principal Investigator
  09/15/21 – 09/14/31

Publications

• Tu SM, Chen JZ, Singh SR, [et al., including Maraboyina S]. Stem Cell Theory of Cancer: Clinical Implications for Cellular Metabolism and Anti-Cancer Metabolomics. Cancers. 2024 16(3). PMID: 38339375. PMCID: PMC10854810.
• Tu SM, Aydin AM, Maraboyina S, [et al.]. Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy. Cancers. 2023 15(22). PMID: 38001645. PMCID: PMC10670143.
• Nissen C, Ying J, Kalantari F, [et al., including Maraboyina S]. A Prospective Study Measuring Resident/Faculty Contour Concordance: A Potential Tool for Quantitative Assessment of Residents' Performance in Contouring and Target Delineation in Radiation Oncology Residency. Journal of the American College of Radiology : JACR. 2023. PMID: 37844655.
• Boria AJ, Narayanasamy G, Bimali M, [et al., including Maraboyina S]. Cleaning the dose falloff with low modulation in SBRT lung plans. Biomedical physics & engineering express. 2023 9(4). PMID: 37140156.
• Tu SM, Aydin AM, Maraboyina S, [et al.]. Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care. Cancers. 2023 15(9). PMID: 37173982. PMCID: PMC10177345.
• Hallgren E, Ayers BL, Moore R, [et al., including Maraboyina S]. Facilitators and barriers to employment for rural women cancer survivors. Journal of cancer survivorship : research and practice. 2022. PMID: 35142993.
• Patel M, Bimali M, Howie C, [et al., including Maraboyina S]. The Role of Radiotherapy Among Patients With Prostate Ductal Adenocarcinoma. Clinical genitourinary cancer. 2021 19(1):e41-e50. PMID: 33616071.
• Patel MA, Fazli Y, Sivakumar S, [et al., including Maraboyina S]. Brachytherapy vs external beam therapy among NSCLC patients undergoing limited surgical resection. Journal of cancer research and clinical oncology. 2020. PMID: 32940781.
• Patel M, Li C, Aronson JH, [et al., including Maraboyina S]. The effect of post mastectomy radiation therapy on survival in breast cancer patients with N1mic disease. Breast (Edinburgh, Scotland). 2020 51:50-56. PMID: 32213441. PMCID: PMC7375567.
• Patel M, Im J, Ivy A, [et al., including Maraboyina S]. The epidemiology and role of surgery in the treatment of urethral clear cell carcinoma. International urology and nephrology. 2020 52(1):51-57. PMID: 31555949.
• Patel M, Nowsheen S, Maraboyina S, Xia F. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell & bioscience. 2020 10:35. PMID: 32180937. PMCID: PMC7065339.